Drugs / IVIG-PEG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04561115 | Sep 2020 → Mar 2022 | immunodeficiency disease | Grifols Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVIG-PEG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04561115 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG)” NCT04561115 ↗ |
| Route | Intravenous | “Intravenous infusion.” NCT04561115 ↗ |